At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
MK-6194 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis
In Brief
A Phase 1 clinical trial evaluating MK-6194 and MK-6194-matching placebo for Ulcerative Colitis. Completed, enrolled 57 participants across 17 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesGeorgia, Germany, Hungary, Moldova, Poland, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartOct 2021
Primary CompletionJan 2024
Study CompletionJul 2024
TodayJul 2026
First PostedJun 11, 2021
Enrollment StartOct 14, 2021
Primary CompletionJan 8, 2024
Study CompletionJul 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.1 years ago
Interventions
MK-6194drug
Subcutaneous injection
MK-6194-matching placebodrug
Subcutaneous injection